Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation (Q34325329)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation (English)

1 reference

Europe PubMed Central

1 August 2017

1 reference

based on heuristic

inferred from title

23

object named as

Richard Olsson

1 reference

Europe PubMed Central

1 August 2017

object named as

Mehdi Hamadani

1

0 references

Christopher Dandoy

object named as

Christopher Dandoy

36

0 references

Parameswaran Hari

object named as

Parameswaran N Hari

2

0 references

Robert Peter Gale

38

object named as

Robert Gale

1 reference

Europe PubMed Central

1 August 2017

Hillard M. Lazarus

20

object named as

Hillard M Lazarus

1 reference

Europe PubMed Central

1 August 2017

David G. Maloney

30

object named as

David G Maloney

1 reference

Europe PubMed Central

1 August 2017

28

object named as

Julie M Vose

1 reference

Europe PubMed Central

1 August 2017

25

object named as

David A Rizzieri

1 reference

Europe PubMed Central

1 August 2017

47

object named as

Harry C Schouten

1 reference

Europe PubMed Central

1 August 2017

35

object named as

Amanda Cashen

1 reference

Europe PubMed Central

1 August 2017

Edmund K Waller

50

object named as

Edmund K Waller

1 reference

Europe PubMed Central

1 August 2017

David J. Inwards-Breland

17

object named as

David J Inwards

1 reference

Europe PubMed Central

1 August 2017

32

object named as

Silvia Montoto

1 reference

Europe PubMed Central

1 August 2017

Jeanette Carreras

4

object named as

Jeanette Carreras

1 reference

Europe PubMed Central

1 August 2017

Mitchell S Cairo

44

object named as

Mitchell S Cairo

1 reference

Europe PubMed Central

1 August 2017

Timothy S Fenske

12

object named as

Timothy S Fenske

1 reference

Europe PubMed Central

1 August 2017

31

object named as

Sonali M Smith

1 reference

Europe PubMed Central

1 August 2017

33

object named as

Wael Saber

1 reference

Europe PubMed Central

1 August 2017

Rammurti T Kamble

18

object named as

Rammurti T Kamble

1 reference

Europe PubMed Central

1 August 2017

26

object named as

Bipin N Savani

1 reference

Europe PubMed Central

1 August 2017

29

object named as

Baldeep Wirk

1 reference

Europe PubMed Central

1 August 2017

Leona A Holmberg

16

object named as

Leona A Holmberg

1 reference

Europe PubMed Central

1 August 2017

Reinhold Munker

45

object named as

Reinhold Munker

1 reference

Europe PubMed Central

1 August 2017

Ernesto Rodriguez-Ayala

7

object named as

Ernesto Ayala

1 reference

Europe PubMed Central

1 August 2017

13

object named as

César O Freytes

1 reference

Europe PubMed Central

1 August 2017

43

object named as

Michael Lill

1 reference

Europe PubMed Central

1 August 2017

Taiga Nishihori

22

object named as

Taiga Nishihori

1 reference

Europe PubMed Central

1 August 2017

49

object named as

Patrick J Stiff

1 reference

Europe PubMed Central

1 August 2017

5

object named as

Görgün Akpek

1 reference

Europe PubMed Central

1 August 2017

6

object named as

Mahmoud D Aljurf

1 reference

Europe PubMed Central

1 August 2017

Veronika Bachanova

8

object named as

Veronika Bachanova

1 reference

Europe PubMed Central

1 August 2017

Siddhartha Ganguly

14

object named as

Siddhartha Ganguly

1 reference

Europe PubMed Central

1 August 2017

27

object named as

Melhem Solh

1 reference

Europe PubMed Central

1 August 2017

author name string

Ying Zhang

3

1 reference

Europe PubMed Central

1 August 2017

Andy I Chen

9

1 reference

Europe PubMed Central

1 August 2017

Yi-Bin Chen

10

1 reference

Europe PubMed Central

1 August 2017

Luciano J Costa

11

1 reference

Europe PubMed Central

1 August 2017

Mark S Hertzberg

15

1 reference

Europe PubMed Central

1 August 2017

Edward J Kanfer

19

1 reference

Europe PubMed Central

1 August 2017

David I Marks

21

1 reference

Europe PubMed Central

1 August 2017

Nishitha M Reddy

24

1 reference

Europe PubMed Central

1 August 2017

Onder Alpdogan

34

1 reference

Europe PubMed Central

1 August 2017

Robert Finke

37

1 reference

Europe PubMed Central

1 August 2017

John Gibson

39

1 reference

Europe PubMed Central

1 August 2017

Jack W Hsu

40

1 reference

Europe PubMed Central

1 August 2017

Nalini Janakiraman

41

1 reference

Europe PubMed Central

1 August 2017

Mary J Laughlin

42

1 reference

Europe PubMed Central

1 August 2017

Phil A Rowlings

46

1 reference

Europe PubMed Central

1 August 2017

Thomas C Shea

48

1 reference

Europe PubMed Central

1 August 2017

publication date

5 July 2014

1 reference

Europe PubMed Central

1 August 2017

Biology of Blood and Marrow Transplantation

1 reference

Europe PubMed Central

1 August 2017

20

1 reference

Europe PubMed Central

1 August 2017

11

1 reference

Europe PubMed Central

1 August 2017

1729-1736

1 reference

Europe PubMed Central

1 August 2017

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Controversies in BMT for lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

6 July 2018

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

Quantification of the completeness of follow-up.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4194275

28 October 2018

Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era

1 reference

https://pubmed.ncbi.nlm.nih.gov/25008330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25008330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25008330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25008330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.BBMT.2014.06.036

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34325329&oldid=1949812591"